Last reviewed · How we verify
Hebei Senlang Biotechnology Inc., Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
0 Phase 3
2 Phase 2
9 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
Therapeutic area mix
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- AffyImmune Therapeutics, Inc. · 1 shared drug class
- Allife Medical Science and Technology Co., Ltd. · 1 shared drug class
- Chongqing Precision Biotech Co., Ltd · 1 shared drug class
- Memorial Sloan Kettering Cancer Center · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Hebei Senlang Biotechnology Inc., Ltd.:
- Hebei Senlang Biotechnology Inc., Ltd. pipeline updates — RSS
- Hebei Senlang Biotechnology Inc., Ltd. pipeline updates — Atom
- Hebei Senlang Biotechnology Inc., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Hebei Senlang Biotechnology Inc., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hebei-senlang-biotechnology-inc-ltd. Accessed 2026-05-18.